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Abstract
Background: Cigarette smoking is the principal environmental risk factor for developing COPD, and nicotine
dependence strongly influences smoking behavior. This study was performed to elucidate the relationship between
nicotine dependence, genetic susceptibility to nicotine dependence, and volumetric CT findings in smokers.
Methods: Current smokers with COPD (GOLD stage ≥ 2) or normal spirometry were analyzed from the COPDGene
Study, a prospective observational study. Nicotine dependence was determined by the Fagerstrom test for nicotine
dependence (FTND). Volumetric CT acquisitions measuring the percent of emphysema on inspiratory CT (% of lung
<-950 HU) and gas trapping on expiratory CT (% of lung <-856 HU) were obtained. Genotypes for two SNPs in the
CHRNA3/5 region (rs8034191, rs1051730) previously associated with nicotine dependence and COPD were analyzed
for association to COPD and nicotine dependence phenotypes.
Results: Among 842 currently smoking subjects (335 COPD cases and 507 controls), 329 subjects (39.1%) showed
high nicotine dependence. Subjects with high nicotine dependence had greater cumulative and current amounts
of smoking. However, emphysema severity was negatively correlated with the FTND score in controls (r = -0.19, p
< .0001) as well as in COPD cases (r = -0.18, p = 0.0008). Lower FTND score, male gender, lower body mass index,
and lower FEV1 were independent risk factors for emphysema severity in COPD cases. Both CHRNA3/5 SNPs were
associated with FTND in current smokers. An association of genetic variants in CHRNA3/5 with severity of
emphysema was only found in former smokers, but not in current smokers.
Conclusions: Nicotine dependence was a negative predictor for emphysema on CT in COPD and control smokers.
Increased inflammation in more highly addicted current smokers could influence the CT lung density distribution,
which may influence genetic association studies of emphysema phenotypes.
Trial registration: ClinicalTrials (NCT): NCT00608764
Introduction
Cigarette smoking is the most important environmental
risk factor for the development of COPD [1-3]. Cigarette
smoking intensity is known to be associated with clinical
features of COPD such as the rate of lung function
decline [2,4] and COPD exacerbation frequency [5,6]. In
addition, it is correlated with symptoms of chronic
bronchitis even in healthy smokers [7]. However, the
correlation between the amount of lifetime smoking
measured as pack-years and the severity of emphysema
on chest CT scans is weak [8,9]. Although the extent of
exposure to cigarette smoke is usually measured in
pack-years, this metric does not reflect other aspects of
smoking behaviors such as depth of inhalation, number
of puffs per cigarette, and age of onset of smoking [10].
Nicotine dependence develops in many smokers, and
smokers with dependency to nicotine tend to have
increased smoking intensity [11]. Thus, nicotine depen-
dence may increase the impact of smoking exposure due
to altering the frequency or depth of smoke inhalation,
even in COPD patients with the same pack-year history.
As a result, it is reasonable to hypothesize that increased
dependence to nicotine would facilitate the development
and progression of COPD. Detailed phenotyping of
COPD includes measures of emphysema severity and air
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any medium, provided the original work is properly cited.trapping determined by quantitative analysis of chest CT
scans. These radiographic measurements have been cor-
related with respiratory symptoms and physiologic para-
meters [12,13]. Despite the highly plausible connection,
there have not been reports documenting an association
between nicotine dependence and the radiographic fea-
tures of COPD.
It has been reported that nicotine addiction is influ-
enced by alpha-nicotinic acetylcholine receptor (nAChR)
variants on chromosome 15 [10,11,14,15]. This genetic
locus is also associated with lung cancer [16,17] and has
been reported as one of the major susceptibility loci
identified by a genome-wide association study (GWAS)
in COPD [14]. To understand the relationship of this
genetic locus to COPD susceptibility, it is important to
understand its impact on nicotine dependence and
COPD-related phenotypes. Recently, it was reported
that the 15q25 locus of the nAChR (CHRNA3/5) was
associated with presence and severity of emphysema,
but an association of this genetic locus with nicotine
addiction measured by the number of pack-years was
not found, and more than half of the subjects were ex-
smokers [18]. Therefore, we assessed the association of
nicotine dependence measured by the Fagerstrom test
for nicotine dependence (FTND), SNPs previously
related to nicotine dependence on chromosome 15, and
the severity of radiographic features of COPD including
emphysema and gas-trapping. We hypothesized that
increased nicotine dependence would be correlated with
increased radiographic severity of COPD independent of
pack-years of smoking and that the genetic susceptibility
locus on chromosome 15 would be associated with nico-
tine dependence and the radiographic features of COPD.
Methods
Subjects
The Genetic Epidemiology of COPD (COPDGene)
Study (http://www.copdgene.org/) is a multicenter pro-
spective observational study designed to identify genetic
factors associated with COPD and to characterize
COPD-related phenotypes [19]. This study recruited
COPD cases and smoking controls who were non-
Hispanic whites and African Americans ages 45 to 80
with at least 10 pack-years of smoking history. This ana-
lysis is based on the first 2500 eligible subjects enrolled
into COPDGene at 21 clinical centers across the United
States (April 2010 COPDGene data set). In this analysis,
COPD was defined by GOLD stage ≥ II criteria of post-
bronchodilator FEV1 <80% predicted and FEV1/FVC
ratio <0.7 [3]. Subjects with GOLD stage 1 or GOLD-
unclassified (FEV1 <80% predicted and FEV1/FVC >0.7)
were excluded to focus our investigation on a compari-
son of COPD subjects with definite reductions in FEV1
and smoking controls.
The Fagerstrom Test for Nicotine Dependence (FTND)
[20,21] was included in the COPDGene study question-
naires to assess nicotine dependence in current smokers
only. The detailed enrollment criteria and phenotyping
methods in the COPDGene study have been described
elsewhere [19]. This analysis included only the COPD
cases and controls who were current smokers at study
enrollment with available FTND scores. In the analysis of
genetic association with emphysema, ex-smokers were
also tested to assess the differences of the association evi-
dence according to current smoking status.
CT imaging
Using multi-detector CT scanners with at least 16 detec-
tor channels, an inspiratory chest CT at 200 mAs was
performed to assess for percent of emphysema (% of
lung <-950 HU) and an expiratory chest CT at 50mAs
was performed to measure air trapping (% of lung <-856
HU). Lung volumes including total lung capacity (TLC)
and functional residual capacity (FRC) were also deter-
m i n e df r o mt h ec h e s tC Ts c a n su s i n g3 D - S L I C E Rs o f t -
ware (http://www.slicer.org). Since Siemens Sensation 64
CT scanners with the B31f reconstruction kernel had an
outlier pattern of lung density distribution, we included
a covariate for CT scans performed on that platform.
The extent of emphysema was classified in four groups
according to the percent of emphysema: none or trivial
(<5% of lung involved), mild (5-25%), moderate
(25-50%), or severe (>50%) [22]. Airway wall area at a
lumen perimeter of 10 mm and quantitative emphysema
measurement have been reported to contribute indepen-
dently to airflow obstruction in COPD [22]. Airway wall
area was estimated from the relationship between square
root of airway wall area and airway luminal perimeter
for a hypothetical 10 mm luminal perimeter (Pi10)a i r -
way using VIDA [23,24]. In this analysis, Pi10 data were
available in 359 control subjects (70.8%) and 261 COPD
cases (77.9%).
SNP genotyping
The A-allele for rs1051730 in the CHRNA3/5 locus has
been associated with reduced FEV1, reduced diffusing
capacity, and increased risk of emphysema on CT [18],
and the C-allele for rs8034191 has been reported to
increase the susceptibility to COPD and lung cancer
[14,25]. We tested the genotypes of these two SNPs in
the CHRNA3/5 locus (rs8034191, rs1051730) on chro-
mosome 15 using TaqMan genotyping in a subset of
COPDGene subjects.
Detailed genotyping and quality control methods as
well as the associations between these SNPs and COPD
have been previously reported by our group [26].
Association analysis of these SNPs was limited to non-
Hispanic White COPD cases and control subjects.
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The total score of FTND was used as a quantitative pheno-
type. For the qualitative analysis of severity of nicotine
dependence, subjects were dichotomized into a group with
nicotine dependence (high dependence, FTND ≥ 6) or not
(no/low dependence, FTND ≤ 5). As percent of emphy-
sema on chest CT was non-normally distributed, natural
log-transformed values were calculated to improve the nor-
mality. As the number of subjects with available Pi10 values
was limited, Pi10 was not included in multivariate analysis.
Univariate analyses were done using the chi-square test for
categorical variables and the student t-test or ANOVA for
continuous variables. Cochran-Armitage trend test was
also used for categorical variables. Significance of correla-
tion was determined by Pearson coefficient and its p-value.
For assessing the determinants of the severity of emphy-
sema and gas trapping on chest CT, linear regression ana-
lysis was performed. In multivariate analyses, statistically
significant variables from the univariate analyses and addi-
tional clinically relevant variables were inserted in the mod-
els as covariates. To test the association with SNPs and key
phenotypes, an additive model with linear regression analy-
sis for continuous variables was applied. Statistical analysis
was done using SAS (version 9.1) and statistical signifi-
cance was determined by a p-value < 0.05.
Results
Characteristics of study subjects
Eight hundred forty-two subjects out of the first 2500
COPDGene subjects were currently smoking COPD or con-
trol subjects with a complete FTND score. The baseline
characteristics of 507 current smokers without airflow
obstruction and 335 COPD subjects with GOLD stage ≥ II
are listed in Table 1. COPD subjects were older in age, and
white race was more common among COPD cases. As
expected, COPD subjects showed more severe airflow
obstruction than smoking controls with compatible radio-
graphic findings. Emphysema severity and air-trapping were
more severe, and airway wall area was greater in COPD sub-
jects. Mean FTND score, percentage of cases with high nico-
tine dependence (FTND score ≥6), the age started smoking,
and the current number of cigarettes smoked daily were not
different between COPD cases and control subjects,
although the total amount of smoking in pack-years and
average number of cigarettes smoked per day were higher in
COPD subjects. There was no difference in the number of
cases tested with a Siemens Sensation-64 CT scanner (17.6%
for controls vs. 18.5% for COPD, p = 0.72), which generally
showed a higher score of emphysema severity.
Clinical characteristics of study subjects by the severity
of nicotine dependence
The clinical characteristics of subjects with low and
high values for FTND are shown in Table 2. When the
subjects were dichotomized according to the severity of
nicotine dependence (No/low dependence vs. high
dependence), there was no difference in the percentage
of subjects with high nicotine dependence between con-
trol and COPD groups (Table 2). The percentages of
subjects in six FTND severity classes were also not dif-
ferent between control and COPD subjects (Additional
file 1: Table S1). However, a decreasing number of
highly addicted COPD subjects was found with increas-
ing GOLD stages (p = 0.004 for trend, Table 2 and
Additional file 1: Figure S1). COPD subjects showed
lower FEV1 (% predicted) and FEV1/FVC in the low
nicotine dependence group. These findings might reflect
efforts to reduce smoking intensity in more severely
affected subjects. In controls, subjects with high nicotine
dependence showed lower FEV1 (% predicted) than sub-
jects with low nicotine dependence even though all
values were within the normal range (p = 0.047). Sub-
jects with low FTND scores were older than those with
severe dependence. In an analysis of racial distributions,
white race proportion was higher in the full set of sub-
jects with high FTND than in subjects with low FTND
( 6 2 . 9 %v s .5 5 . 0 % ,p=0 . 0 2 ) .H o w e v e r ,a ne l e v a t e dp r o -
portion of white subjects with high FTND was found
only in the COPD group. In terms of smoking beha-
viors, the total amount of pack-years and the current
number of cigarettes smoked daily were higher and
smoking starting age was earlier in the group with
Table 1 Baseline characteristics of currently smoking
subjects*
Variables Control
(n = 507)
COPD
(n = 335)
p
Age, years 53.8 ± 6.9 59.2 ± 7.8 <.0001
Male, n (%) 276(54.4) 185(55.2) 0.82
White, n (%) 245(48.3) 244(72.8) <.0001
BMI, kg/m
2 28.5 ± 5.9 27.1 ± 5.8 0.001
FTND score 4.6 ± 2.5 4.7 ± 2.4 0.49
Nicotine dependence
(FTND ≥6), n (%)
196(38.7) 133(39.7) 0.76
Smoking amount, pack-years 37.2 ± 19.2 51.7 ± 28.8 <.0001
Average number of cigarette
smoked per day
20.2 ± 8.9 23.8 ± 10.8 <.0001
Cigarettes/day, current 16.9 ± 9.8 17.3 ± 10.8 0.56
Smoking starting age, years 17.0 ± 5.3 16.4 ± 4.8 0.09
FEV1/FVC, ratio 0.79 ± 0.05 0.53 ± 0.12 <.0001
FEV1, % of predicted 97.6 ± 12.3 55.2 ± 16.4 <.0001
% Emphysema at -950 HU
‡, % 1.84 ± 2.21 8.81 ± 9.75 <.0001
% Gas trapping, % 10.5 ± 9.9 32.9 ± 19.3 <.0001
Pi10 3.75 ± 0.12 3.81 ± 0.12 <.0001
*Data listed in number (%) for frequency or mean ± standard deviation for
quantitative variables.
† The number of cases evaluated with Siemens Sensation CT scanner with
64 channels.
‡ For epidemiologic and genetic analysis, log transformed values were used.
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Symptoms of chronic bronchitis were more prevalent in
COPD subjects with high nicotine dependence, and a
similar trend was found in controls (Table 2).
The correlation between radiographic parameters and the
severity of nicotine dependence
In COPD subjects, the percent of emphysema and gas-
trapping were greater in subjects with low FTND scores
(Table 2). When COPD subjects were classified by the
extent of emphysema, cases with more severe emphysema
showed lower FTND scores (p = 0.001, Table 3). This rela-
tionship was also consistent when the FTND score was
tested as a quantitative variable and the same pattern was
also observed in controls (Figure 1). However, when com-
parisons were limited to subjects within a particular GOLD
class, the statistical significance of negative correlations
between FTND and emphysema was marginal (r = -0.13,
p = 0.07 for subjects with GOLD II, r =- 0 . 1 7 ,p=0 . 0 6f o r
GOLD III-IV). In correlation analysis of FTND score with
other radiographic variables including percent of gas-
trapping and airway wall thickness measured on chest CT,
Table 2 Baseline characteristics classified by the presence of nicotine dependence
Variables No/Low dependence
(n = 513)
High dependence
(n = 329)
p
Subjects Control 311(61.3) 196 (38.7) 0.76
COPD 202(60.3) 133(39.7)
COPD stage GOLD II 116(55.0) 95(45.0) 0.02
GOLD III 66(66.7) 33(33.3)
GOLD IV 20(80.0) 5(20.0)
Spirometry
FEV1/FVC % Control 0.79 ± 0.05 0.79 ± 0.05 0.25
COPD 0.52 ± 0.13 0.54 ± 0.11 0.03
FEV1pred % Control 98.5 ± 12.5 96.3 ± 11.9 0.047
COPD 53.5 ± 17.2 57.8 ± 14.7 0.02
Demographic
Age, year Control 54.8 ± 7.4 52.3 ± 5.8 <.0001
COPD 60.0 ± 8.0 57.9 ± 7.5 0.02
Male, n (%) Control 158(50.8) 118(60.2) 0.04
COPD 107(53.0) 78(58.7) 0.31
White, n (%) Control 147(47.3) 98(50.0) 0.55
COPD 135(66.8) 109(82.0) 0.002
Smoking related
Pack-years of smoking Control 32.2 ± 15.6 45.2 ± 21.5 <.0001
COPD 45.8 ± 23.4 60.6 ± 33.7 <.0001
Average number of cigarettes smoked per day Control 17.3 ± 7.4 24.8 ± 9.2 <.0001
COPD 21.0 ± 8.7 28.1 ± 12.2 <.0001
Cigarettes/day, current Control 12.7 ± 7.3 23.6 ± 9.7 <.0001
COPD 12.4 ± 7.8 24.8 ± 10.5 <.0001
Smoking starting age, years Control 17.5 ± 5.5 16.2 ± 4.9 0.01
COPD 17.0 ± 4.9 15.5 ± 4.6 0.01
Symptom
Chronic bronchitis symptoms*, n (%) Control 49(15.8) 43(21.9) 0.08
COPD 64 (31.7) 72(54.1) <.0001
Radiographic
% Emphysema at -950 HU, % Control 2.1 ± 2.4 1.5 ± 1.9 0.01
COPD 10.5 ± 10.8 6.2 ± 7.1 <.0001
% Gas trapping, % Control 10.7 ± 9.9 10.1 ± 9.9 0.52
COPD 36.0 ± 20.6 28.3 ± 16.3 0.001
Pi10 Control 3.75 ± 0.13 3.75 ± 0.11 0.72
COPD 3.80 ± 0.12 3.83 ± 0.12 0.11
* Chronic bronchitis is defined as cough for 3 mos/yr for at least 2 years along with phlegm for 3 mos/yr for at least 2 years.
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correlated with FTND only in COPD cases (r =- 0 . 1 9 ,
p = 0.001). Airway wall thickness did not show any
significant correlation with FTND score in COPD
cases or control subjects. In terms of radiographic
parameters, current smokers showed less extensive
emphysema and gas trapping than ex-smokers in con-
trols and COPD subjects although currently smoking
COPD cases had less severe airflow obstruction than
ex-smoking COPD cases (Additional file 1: Table S2).
This finding was consistent for emphysema and gas
trapping when COPD subjects were stratified within
GOLD stages (GOLD II vs. GOLD III-IV).
The determinants of the severity of emphysema and
gas trapping
To determine the effect of FTND score on the severity
of emphysema and gas trapping, multivariate analysis
was done. In addition to FTND score, other significant
predictors of emphysema and gas trapping from univari-
ate analysis were included: age, gender, race, BMI, FEV1
(% predicted), type of CT scanner, and smoking inten-
sity in pack-years (Table 4).
In terms of the severity of emphysema, FTND score was as
an independent predictor of emphysema despite adjusting
for the total amount of smoking in pack-years but, as in the
univariate analysis, the direction was negative rather than
Table 3 Differences in smoking variables by the extent of emphysema on chest CT in COPD subjects
Extent of emphysema (%)*
Variables None/Trivial (<5%)
(n = 167)
Mild (5-25%)
(n = 134)
Moderate (25-50%)
(n = 31)
P
FTND severity 0.0008
†
No/low dependence 89(44.3) 85(42.3) 27(13.4)
High dependence 78(59.5) 49(37.4) 4(3.0)
FTND score 5.0 ± 2.4 4.7 ± 2.4 3.4 ± 2.0 0.001
Smoking starting age, years 16.6 ± 5.1 16.3 ± 4.6 15.6 ± 4.4 0.53
Pack-years of smoking 47.5 ± 22.2 57.6 ± 35.1 49.7 ± 27.7 0.01
Average number of cigarettes smoked per day 23.3 ± 9.2 25.0 ± 12.8 22.0 ± 9.4 0.24
Cigarettes/day, current 18.8 ± 10.2 16.9 ± 11.8 11.1 ± 7.3 0.001
*data of extent of % emphysema were missing in 3 subjects of COPD subjects.
† p value for Fisher’s Exact Test.
Figure 1 The correlation of FTND score with emphysema severity on chest CT in controls (left; log (%emphysema) = 4.33-(0.09 ×
FTND score), p < .0001) and COPD subjects (right; log (%emphysema) = 5.87-(0.10 × FTND score), p = 0.0008).
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severity of nicotine dependence was considered as a dichoto-
mous variable instead of a quantitative FTND score, the sta-
tistical significance was consistent (b = -0.44, p = 0.002 for
COPD and b = -0.27, p = 0.007 for control subjects).
When each multivariate model was adjusted for the
number of daily cigarettes smoked currently instead of
pack-years, the significance of FTND was persistent
in only control subjects for severity of emphysema (b =-
0.06, p = 0.008 for controls; b = -0.02, p = 0.57 for
COPD) and the effect of FTND on gas trapping failed
to reach statistical significance (b = 0.38, p = 0.12 for
controls; b = -0.08, p = 0.86 for COPD). A significant
interaction between FEV1 and FTND was not found.
The association among candidate SNPs, nicotine
dependence, and radiographic findings
Genotyping data for 312 currently smoking subjects
with FTND scores (146 cases with COPD and 166 smo-
ker controls) were available. In the full group of
currently smoking subjects, the A-allele of rs1051730
was associated with increased FTND score, while neither
SNP in the CHRNA3/5 region (rs8034191 and
rs1051730) was associated with FEV1 (% predicted),
affection status of COPD, nor percent of emphysema
(Table 5). In stratified analysis, these SNPs were asso-
ciated with increasing pack-years in currently smoking
control subjects.
In multivariate models, addition of either the A-allele
of rs1051730 or the C-allele of rs8034191 was signifi-
cantly associated with increased FTND score indepen-
dent of age and gender in the full study population of
current smokers but not in currently smoking COPD
cases only (Table 6). We adjusted for case-control status
in models for FTND in the full set of currently smoking
case and control subjects, and significant associations
remained (p = 0.045 for rs8034191 and p = 0.01 for
rs1051730).
When the analysis was extended to include 681 COPD
or control ex-smokers with genotyping data, both
Table 4 The results of multivariate regression analysis for the severity of emphysema and gas-trapping*
Log (% emphysema) % gas-trapping
Group COPD Control COPD Control
variables b p b p b p b p
Age 0.01 0.17 0.01 0.06 0.23 0.046 0.32 <.0001
Female -0.69 <.0001 -0.60 <.0001 -5.72 0.0003 -2.14 0.02
African-
American
-0.10 0.51 -0.26 0.01 1.01 0.59 0.24 0.80
BMI, kg/m
2 -0.06 <.0001 -0.01 0.12 -1.04 <.0001 -0.28 0.0003
FEV1pred% -0.03 <.0001 0.01 0.002 -0.69 <.0001 -0.003 0.94
FTND score -0.07 0.01 -0.07 0.0003 -0.62 0.09 -0.04 0.92
Pack-years of
smoking
0.003 0.25 0.002 0.50 0.03 0.36 -0.02 0.49
*Additionally adjusted for CT scanner model.
Table 5 The association with SNPs of CHRNA3/5 and nicotine dependence, lung function, and emphysema severity
in current smokers
SNP (Chr. 15) rs8034191 rs1051730
Genotype (Number of subjects) TT(126) TC(145) CC(38) p GG(129) GA(137) AA(36) p
COPD affection 49(38.9) 78(53.8) 17(44.7) 0.13 50(38.8) 72(52.6) 16(44.4) 0.14
FTND score Combined (312) 4.5 ± 2.4 5.0 ± 2.6 5.1 ± 2.6 0.12 4.5 ± 2.4 5.1 ± 2.7 5.3 ± 2.6 0.03
COPD (146) 4.8 ± 2.2 5.1 ± 2.6 5.4 ± 2.2 0.35 4.7 ± 2.2 5.3 ± 2.6 5.1 ± 2.1 0.27
Control (166) 4.3 ± 2.5 4.9 ± 2.7 4.8 ± 3.0 0.29 4.3 ± 2.5 4.8 ± 2.8 5.5 ± 2.9 0.08
Pack-years of smoking Combined 46.2 ± 28.2 49.5 ± 24.2 47.1 ± 25.9 0.56 45.9 ± 27.8 49.7 ± 25.2 47.2 ± 24.6 0.46
COPD 60.0 ± 36.5 55.8 ± 27.2 47.4 ± 26.3 0.16 59.3 ± 36.3 56.8 ± 28.7 45.4 ± 22.3 0.18
Control 37.4 ± 16.1 42.1 ± 17.8 46.8 ± 26.2 0.02 37.4 ± 16.0 41.8 ± 17.8 48.7 ± 26.7 0.01
FEV1%pred Combined 80.4 ± 25.0 72.1 ± 26.6 78.2 ± 24.5 0.14 80.2 ± 25.2 74.4 ± 25.5 77.6 ± 25.0 0.21
COPD 54.1 ± 16.8 51.8 ± 18.4 56.4 ± 16.3 0.96 53.6 ± 16.9 54.6 ± 17.6 55.4 ± 17.7 0.69
Control 97.1 ± 11.0 95.8 ± 9.9 95.9 ± 12.9 0.49 97.0 ± 10.9 96.4 ± 10.0 95.3 ± 12.7 0.50
Log(%emphysema) Combined 4.7 ± 1.4 5.0 ± 1.3 4.6 ± 1.4 0.57 4.7 ± 1.4 4.9 ± 1.2 4.7 ± 1.5 0.60
COPD 5.5 ± 1.2 5.6 ± 1.2 5.5 ± 1.4 0.87 5.6 ± 1.2 5.5 ± 1.2 5.8 ± 1.2 0.82
Control 4.2 ± 1.2 4.3 ± 1.0 4.0 ± 1.0 0.78 4.2 ± 1.2 4.3 ± 1.0 3.9 ± 0.9 0.61
Kim et al. Respiratory Research 2011, 12:9
http://respiratory-research.com/content/12/1/9
Page 6 of 11rs1051730 and rs8034191 showed significant associa-
tions with emphysema severity (p < 0.05); stratified ana-
lysis suggested that this association was likely being
driven primarily by COPD subjects, since trends for
association were observed in COPD subjects but not
control subjects.
Discussion
In this study, we described the relationships among
nicotine dependence, a proven genetic susceptibility
locus for nicotine dependence and COPD, and struc-
tural measures of COPD, including severity of emphy-
sema and air-trapping on chest CT in COPD and non-
COPD smoking controls. Although recently there was a
report on the association of a SNP in the nAChR gene
with emphysema severity [18], to our knowledge, this is
the first analysis of the relationship among these three
conditions in current smokers. Compatible with pre-
v i o u sr e p o r t s ,F T N Ds c o r e si no u rs t u d yp o p u l a t i o n
were correlated with the cumulative intensity of smok-
ing in pack-years, daily amount of smoking, and younger
age of smoking initiation [27,28]. In addition, the cumu-
lative intensity of smoking in pack-years was correlated
with lower lung function and emphysema. Nevertheless,
contrary to our initial hypothesis, FTND score was
negatively correlated with emphysema severity in both
COPD and control subjects. In addition, FTND score
decreased as COPD severity, assessed by GOLD stage,
increased. We observed significant associations of
rs8034191 and rs1051730 in the CHRNA3/5 locus with
FTND score, but we found differential evidence for
association of SNPs related to nicotine dependence with
emphysema severity according to current smoking
status.
Although nicotine was reported to inhibit apoptosis
through the muscarinic acetylcholine receptor in some
cell lines [29-31], any beneficial effect of current smok-
ing on emphysema is extremely unlikely. There are sev-
eral possible explanations for our finding of less
quantitative radiographic emphysema and less severe
COPD in subjects with greater nicotine addiction. The
first potential explanation is selection bias in the study
population, namely the ‘healthy smoker effect’ and/or
‘survivor effect’. Cigarette smoking causes functional
impairments such as troublesome sputum and cough,
dyspnea, decrease in exercise capacity, and increased
risk of mortality in subjects with COPD. These negative
effects provide incentive to quit smoking, which is
greater in more severely affected individuals. Since
FTND score could be measured only in current smo-
kers, affected subjects who have quit smoking are not
included in our analysis. The development of COPD
and the progression to more severe COPD could also
lead to a reduction in daily smoking intensity among
those individuals that continue to smoke; since the
number of cigarettes currently smoked per day is part of
the FTND, efforts to taper smoking could appear as a
reduction in nicotine dependence. The observation that
COPD subjects had greater average cigarettes smoked
per day but similar current cigarettes smoked per day
compared to control subjects (Table 1) suggests that
some reduction in smoking intensity among COPD sub-
jects has occurred with disease development. Since the
d a i l yc i g a r e t t eu s a g ei so n l yo n ec o m p o n e n to ft h e
Table 6 Multivariate analysis for the association with SNPs of CHRNA3/5 and nicotine dependence and emphysema
severity in current smokers and ex-smokers
SNP (Chr. 15) CHRNA3/5
rs8034191 rs1051730
FTND score* Beta SE p Beta SE p
Current smokers Combined (312) 0.45 0.21 0.03 0.53 0.21 0.01
COPD (146) 0.32 0.30 0.30 0.29 0.31 0.35
Control(166) 0.51 0.28 0.07 0.66 0.28 0.02
Log (%emphysema)
†
Current smokers Combined (312) 0.02 0.10 0.83 0.03 0.10 0.77
COPD (146) -0.005 0.15 0.98 0.01 0.15 0.93
Control (166) 0.06 0.10 0.58 0.03 0.11 0.76
Ex-smokers Combined (681) 0.14 0.07 0.047 0.14 0.07 0.049
COPD (344) 0.14 0.08 0.06 0.13 0.08 0.10
Control (337) -0.03 0.07 0.68 -0.02 0.07 0.75
Current and ex-smokers Combined (985) 0.11 0.06 0.06 0.12 0.06 0.05
COPD (490) 0.14 0.07 0.06 0.14 0.07 0.07
Control (495) -0.001 0.06 0.99 -0.002 0.06 0.98
* Adjusted for age and gender.
† Adjusted for age, gender, BMI, and CT scanner; current smokers included only the subjects with available FTND scores.
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smoked per day on our results is uncertain.
Premature death may also lead to the exclusion of
advanced COPD cases with severe emphysema or gas
trapping from this study. This possibility is supported
by the fact that the proportion of advanced stages of
COPD was relatively low in this study population, and
ex-smokers showed more severe obstruction on spiro-
metry (Additional file 1; Table S2). The FTND may not
reflect every aspect of nicotine dependence [32] and
does likely have limitations in assessing nicotine depen-
dence cross-sectionally in a smoking group of COPD
subjects. Nevertheless, FTND has been validated for its
usefulness in general population samples [20,21,32] and
is widely used in studies including COPD populations
[33,34]. Furthermore, in this study, the negative correla-
tion between FTND and emphysema severity was found
even in controls without airflow obstruction and in
cases with mild-to-moderate COPD. Therefore, selection
bias and the limitations of applying the FTND in COPD
patients, likely do not explain all of our results.
Another plausible explanation for the negative associa-
tion of FTND score with emphysema is interference in
measuring the radiographic outcome variable of percent
emphysema on quantitative chest CT scan analysis.
Smoking induces airway irritation and inflammation and
results in accumulation of mucus and inflammatory
cells including neutrophils, macrophages, and lympho-
cytes in small airways even in subjects without airflow
obstruction [35-37]. A previous study has shown that
the count of inflammatory cells within small airway
walls is correlated with the smoking intensity in pack-
years and is higher in current than ex-smokers [35].
Camiciottoli et al. also reported that emphysema sever-
ity was higher in former smokers than in current smo-
kers [38] as we observed in our study. Therefore, since
subjects with higher dependence on nicotine tended to
have greater current smoking exposures, those with
higher FTND likely had more inflammatory changes in
peripheral airways and alveoli which could be associated
with increased lung density. Supporting this hypothesis,
the effect of FTND on emphysema severity in multivari-
ate analysis decreased and the effect on gas trapping dis-
appeared after adjusting for the current number of
cigarettes smoked per day. In addition, the association
of nicotine addiction risk alleles with emphysema
severity changed toward significant relationships in ex-
smokers. Therefore, the hypothesis that measuring
emphysema severity on chest CT might have limitations
in current smokers may explain the differential genoty-
pic association of SNPs with emphysema severity on
chest CT according to their smoking status. The detec-
tion of significant genetic associations to quantitative
CT emphysema phenotypes may be limited in current
smokers due to this potential effect of current smoking
on lung inflammation.
In smokers’ lungs, emphysema is not the only possible
phenotype and other pathological processes may
increase lung density, including interstitial lung disease
or other subclinical parenchymal diseases [39,40].
Lederer et al reported an increase of high attenuation
areas with an increasing of amount of smoking even in
healthy smokers [39]. This may also be the case in our
study population. Considering our findings and previous
reports related to the effects of smoking on CT imaging,
more studies are needed to clarify the clinical signifi-
cance of measuring low lung attenuation in populations
that include current smokers.
In this study, we failed to show an association of nico-
tine dependence candidate SNPs with the severity of
emphysema in current smokers while a significant asso-
ciation of candidate SNPs with nicotine dependence was
found. Contrary to our findings in current smokers,
Lambrechts et al. reported recently that rs1051730, one
of the SNPs that we tested in this study, was associated
with the presence and severity of emphysema while they
did not show association of these SNPs with nicotine
dependence measured by the number of pack-years
smoked instead of FTND [18]. Among the subjects in
Lambrechts’ study, current smokers comprised only
45.6% and 50.7% of their two cohorts, which may
decrease the overall effect of measuring emphysema in
current smokers. They also used visual estimation of
emphysema in one population [18]. These factors may
lead to the differences from the results of our study,
which is supported by the finding that the association of
candidate SNPs with emphysema severity tended to be
significant in our study when genetic association analysis
was applied only in ex-smokers.
The association of SNPs in the CHRNA3/5 locus with
smoking behavior has been was widely reported [41-43],
and our results confirmed it again. We also analyzed
genotypes in only white control subjects and COPD
subjects with definite airflow obstruction (GOLD stage
II-IV) to limit population heterogeneity.
Despite interesting findings, our study has limitations.
As mentioned above, the population of advanced COPD
cases was small, and the analysis across GOLD stages
was limited. Our study sample was relatively small for
genetic association analysis, and we did not include a
replication population. We performed some genetic
association analyses in a combined set of cases and con-
trols. The appropriate adjustment for potential bias in
such analyses is uncertain [44,45]. We performed adjust-
ment for case-control status for FTND, but not for traits
directly related to COPD pathophysiology (e.g. FEV1,
emphysema) since this would likely have been an over-
adjustment. Although these are limitations, they are
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role for these SNPs in nicotine dependence in other
populations.
In summary, FTND score was negatively associated
with the severity of emphysema in COPD and healthy
current smokers, and the FTND score decreased with
increasing GOLD stage. Genetic variants in CHRNA3/5
(rs8034191 and rs1051730) were significantly associated
with nicotine dependence. However, in a relatively small
group of current smokers, an association of genetic var-
iants in CHRNA3/5 (rs8034191 and rs1051730) with
severity of emphysema or air trapping on CT was not
found; the impact of current smoking on CT-measured
emphysema may limit detection of significant genetic
associations.
Conclusion
Increased inflammation in more highly addicted current
smokers could influence the CT lung density distribu-
tion; further investigation of the clinical significance
of these findings will be necessary. While SNPs in
CHRNA3/5 were associated with nicotine dependence
measured with FTND, surprisingly, nicotine dependence
was a negative predictor for emphysema on CT in
COPD patients and even in control smokers. An asso-
ciation of genetic variants in CHRNA3/5 (rs8034191
and rs1051730) with severity of emphysema was found
in former smokers, but not in current smokers. Our
results suggest that current smoking could limit detec-
tion of genetic determinants of quantitative emphysema.
The impact of current smoking status and reduction of
smoking intensity with increased COPD severity need to
be considered in epidemiological, radiological, and
genetic studies of the relationships between nicotine
addiction and COPD.
Additional material
Additional file 1: Epidemiology, radiology, and genetics of nicotine
dependence in COPD. This additional file contains two supplementary
tables to show the distribution of FTND severity in the study population
(Table S1) and the comparative results of subpopulations according to
their smoking status (Table S2). One additional figure (Figure S1) shows
the distribution of subjects with high nicotine dependence across COPD
GOLD stages.
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